Cogent Biosciences, Inc. (COGT) News
Filter COGT News Items
COGT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest COGT News From Around the Web
Below are the latest news stories about COGENT BIOSCIENCES INC that investors may wish to consider to help them evaluate COGT as an investment opportunity.
Cogent Biosciences Announces Participation at Upcoming Investor ConferencesWALTHAM, Mass. and BOULDER, Colo., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer, will participate in the following upcoming investor conferences in February: Guggenheim Healthcare Talks Idea Forum Oncology DayDate/Time: Wednesday, February 8, 2023 at 10:10 a.m. ET SVB Securities Global Biopharm |
Companies Like Cogent Biosciences (NASDAQ:COGT) Are In A Position To Invest In GrowthThere's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining... |
Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer TherapeuticsDemonstrate significant progress toward leadership in Systemic Mastocytosis (SM), including mid-year Part 1 results from Phase 2 APEX trial in AdvSM patients and initial clinical data in 2H23 from Phase 2 SUMMIT trial in NonAdvSM patients Rapidly progress bezuclastinib in 2nd-line Gastrointestinal Stromal Tumors (GIST), with planned clinical update from lead-in portion of Phase 3 PEAK trial in 1H23, and expansion to >100 global clinical sites this yearSelect clinical candidates from ongoing FGFR |
Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare ConferenceWALTHAM, Mass. and BOULDER, Colo., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced that Andrew Robbins, President and Chief Executive Officer will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco on Thursday, January 12, 2023 at 7:30 a.m. PT/10:30 a.m. ET. A live webcast of the presentation will be available on the Investors & |
Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)- 89% ORR in TKI-therapy naïve patients; 73% ORR in all evaluable patients with 27-week median follow-up - Rapid and deep responses seen including first confirmed CR at 20 weeks; 77% of patients with at least 2 cycles of treatment had complete clearance of bone marrow mast cell aggregates - Favorable safety and tolerability profile with no related cognitive effects or reported intracranial bleeding events - Cogent to host investor webcast Monday, December 12 at 8:00 a.m. ET WALTHAM, Mass. and BO |
Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic MastocytosisWALTHAM, Mass. and BOULDER, Colo., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the details of its investor webcast being held on Monday, December 12, 2022 at 8:00 a.m. ET (7:00 a.m. CT) to discuss updated clinical data from its on-going Phase 2 APEX trial evaluating bezuclastinib in patients with Advanced Systemic Mastocytosis being presented at the 6 |
Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical DevelopmentWALTHAM, Mass. and BOULDER, Colo., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Rachael Easton, MD, Ph.D., Vice President, Head of Clinical Development. "We are pleased to welcome Dr. Easton to Cogent as we continue to develop bezuclastinib in Systemic Mastocytosis and GIST,” said Andrew Robbins, the company’s President and Chief Exe |
Analysts Offer Insights on Healthcare Companies: Theravance Biopharma (TBPH), Cogent Biosciences (COGT) and PAVmed (PAVM)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Theravance Biopharma (TBPH – Research Report), Cogent Biosciences (COGT – Research Report) and PAVmed (PAVM – Research Report) with bullish sentiments. Theravance Biopharma (TBPH) SVB Securities analyst David Risinger maintained a Buy rating on Theravance Biopharma today and set a price target of $14.00. The company's shares closed last Wednesday at $11.22. According to TipRanks. |
Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial ResultsPhase 3 PEAK trial initiated comparing bezuclastinib + sunitinib vs. sunitinib alone in second line gastrointestinal stromal tumor (GIST) patients; initial safety and pharmacokinetic data from lead-in phase to be presented at CTOS 2022 Phase 2 APEX trial in Advanced Systemic Mastocytosis (AdvSM); oral presentation at ASH 2022 including assessment of patient response Developed an optimized formulation of bezuclastinib with new dosage strength and over 40% improvement in clinical exposure; potenti |
Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) MeetingCompany to Host Virtual Investor Event on Monday, December 12WALTHAM, Mass. and BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced upcoming presentations for bezuclastinib at the 64th Annual Meeting of the American Society of Hematology (ASH) being held in New Orleans, LA from December 10-13, 2022. The company will also host a virtual investo |